Search Results for: Other News to Note
-
Other News To Note
Celgene International Sarl, of Boudry, Switzerland, a unit of Celgene Corp., said the European Commission amended the marketing authorization application for Revlimid (lenalidomide) so that it is now approved to treat patients with transfusion-dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate...Prior to the submission of an investigational new drug -
Pharma: Other News To Note
The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous formulation of BMS' Orencia (abatacept), for the treatment of rheumatoid arthritis...Costs related to the reorganization are not expected to have a material effect on the group's finances -
Other News To Note
Covidien expects to complete the distribution of Mallinckrodt ordinary shares after the close of trading on the New York Stock Exchange on June 28...As part of that process Royalty Pharma, of New York, will be invited to participate -
Other News To Note
Ohr Pharmaceutical Inc., of New York, said it received confirmation that its application to list on Nasdaq was approved...That is in contrast to some other antibiotics, such as linezolid (Zyvox), which causes drug interactions when taken with selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors...Zealand Pharma A/S, of Copenhagen, signed a collaboration agreement with D.E. Shaw Research LLC., of New York, to combine Shaw's molecular dynamics simulations with Zealand -
Other News To Note
commercial rights to Mugard, a marketed product for the management of oral mucositis, from Access Pharmaceuticals Inc., of Dallas...Edge expects to enroll the first patient in a Phase I/II trial in the third quarter...Xenon plans to initially develop XEN701 for patients with chronic kidney disease who are intolerant of or who are poor responders to erythropoietin (Epo) therapy -
Other News To Note
Aeterna Zentaris Inc., of Quebec City, said the class action lawsuit filed against the company and certain of its officers by Faruqi & Faruqi LLP in the U.S. District Court for the Southern District of New York has been entirely dismissed with prejudice and without leave to amend...Royalty Pharma, of New York, increased its hostile bid to acquire Elan Corp -
Other News To Note
Royalty Pharma, of New York, extended until June 21 the $6.4 billion offer to buy Elan Corp...In addition to the research collaboration, which includes three cancer targets, Isis and AstraZeneca are developing two antisense drugs, ISIS-ARRx and ISIS-STAT3RX, discovered by Isis and licensed to AstraZeneca for the treatment of cancer. (See BioWorld Today, Dec. 12, 2012...The company expects to enter a third agreement (separation agreement) governing other terms of the firms' business relationship -
Other News To Note
BrainStorm Cell Therapeutics Inc., of New York, received the third installment of a 2013 grant from Israel's Office of the Chief Scientist (OCS) for $335,000...Treatment was shown to significantly reverse the pulmonary hypertension associated with advanced stages of the disease and restore cardiovascular function...The therapy is designed to be injected once a week or twice a month, rather than daily, as required by current hGH therapy -
Other News To Note
to purchase all of the outstanding capital stock of ProFibrix, subject to the former's satisfactory review of the pending Phase III trial results with Fibrocaps, a dry powder topical formulation of fibrinogen and thrombin being developed to stop bleeding during surgery -
Other News To Note
CorMedix Inc., of Bridgewater, N.J., received a notice from the New York Stock Exchange that CorMedix made reasonable demonstration of its ability to regain compliance with the exchange's rules, and CorMedix's listing will continue through Oct. 20...AstraZeneca is planning to develop ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy...Maxygen Inc., of Redwood City, Calif., said its -
Pharma: Other News To Note
In other news, Perrigo received approval for the generic version of Sanctura XR (trospium chloride; Allergan Inc.) to treat overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency -
Other News To Note
plc, of Dublin, Ireland, said its board rejected New York-based Royalty Pharma's revised offer to acquire all of Elan's shares for $12.50 per share through its shell subsidiary Echo Pharma Acquisition Ltd., stating that the bid "grossly" undervalued the company...In other news, Elan priced its offering of $850 million aggregate principal amount of 6.25 percent senior notes due 2021 by its wholly owned subsidiaries, Elan Finance public limited co -
Pharma: Other News To Note
It was developed to block the action of orexins, neurotransmitters in a specific part of the brain that help to keep a person awake...Perrigo Co., of Allegan, Mich., is transferring the listing of its U.S.-traded common stock to the New York Stock Exchange (NYSE) from Nasdaq -
Other News To Note
Another revised proposal to approve an amendment to the 2011 Omnibus Incentive Plan, calls for a limit to the amount of the requested increase to 75 million shares of common stock (in the earlier proxy, an increase of 155 million shares was proposed...plc, of Dublin, Ireland, said its board on Thursday rejected New York-based Royalty Pharma's revised offer to acquire all of Elan's shares for $12.50 per share through its shell subsidiary Echo Pharma Acquisition Ltd., stating that the bid "grossly -
Pharma: Other News To Note
Pfizer Inc., of New York, said it intends to split off its remaining interest in Zoetis Inc., of Madison, N.J., the former animal health unit that recently completed its initial public offering -
Other News To Note
The company plans to move ASM-024 into a Phase II trial in COPD later this year...His contributions to the field of oncology include more than 20 compounds brought into development, including the recently approved anticancer drugs Xalkori (crizotinib) and Inlyta (axitinib), discovered at Pfizer where O'Connor served as the global research therapeutic area head for oncology...Relmada Therapeutics Inc., of New York, retained Brio Financial Group and GBH CPAs PC as financial reporting consultant and -
Pharma: Other News To Note
Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs -
Other News To Note
In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies...In other news, closed its initial public offering (IPO) of 3.5 million American depository shares (ADSs) at $8.90 per share...PM01183 is designed to bind covalently to the minor groove of DNA to induce a specific degradation in tumor cells of RNA -
Elan Buying into Theravance, GSK Royalty Stream for $1B
Even after the news broke Monday – and the Theravance share price (NASDAQ:THRX) gained more than 14 percent to hit $40 – the entire company was still only valued at $3.94 billion...Editor's note: To obtain a CD of the webinar, "Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity" or for a deeper dive, BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, call 800-477-6307 -
Other News To Note
The Nasdaq OMX Group Inc., of New York, reported the semi-annual re-ranking of the Nasdaq Biotechnology Index, which will become effective prior to the market's open on May 20...Kinnovata plans to develop, manufacture and commercialize respiratory products for China and other regional Asian markets, initially exploiting Vectura's Clickhaler and Duohaler dry powder inhaler (DPI) technology platforms in asthma and chronic obstructive pulmonary disease
Category
Current Filters
- xNew York
Related Keywords
Categories
- x BioWorld Today (2462)
- x BioWorld International (229)
- x BioWorld Insight (21)
- x Bio Perspectives (14)
- x State of the Industry Report (5)
- x Top 25 Drug Report (2)